Conduit Pharmaceuticals Q2 2024 Earnings Report $0.89 +0.12 (+15.89%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Conduit Pharmaceuticals EPS ResultsActual EPS-$7.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AConduit Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConduit Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/12/2024TimeN/AConference Call ResourcesCDT Earnings History Remove Ads Conduit Pharmaceuticals Earnings HeadlinesConduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline DevelopmentMarch 21, 2025 | nasdaq.comConduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656March 21, 2025 | nasdaq.comThe unusual signal flashing green againSomething fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.March 31, 2025 | ProsperityPub (Ad)Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904March 20, 2025 | markets.businessinsider.comConduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904March 19, 2025 | globenewswire.comConduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price RegainingMarch 8, 2025 | nasdaq.comSee More Conduit Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Conduit Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Conduit Pharmaceuticals and other key companies, straight to your email. Email Address About Conduit PharmaceuticalsConduit Pharmaceuticals (NASDAQ:CDT), a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.View Conduit Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
